KR102560562B1 - Muc16을 표적화하는 암 백신 및 이의 용도 - Google Patents

Muc16을 표적화하는 암 백신 및 이의 용도 Download PDF

Info

Publication number
KR102560562B1
KR102560562B1 KR1020207019764A KR20207019764A KR102560562B1 KR 102560562 B1 KR102560562 B1 KR 102560562B1 KR 1020207019764 A KR1020207019764 A KR 1020207019764A KR 20207019764 A KR20207019764 A KR 20207019764A KR 102560562 B1 KR102560562 B1 KR 102560562B1
Authority
KR
South Korea
Prior art keywords
seq
nucleic acid
acid sequence
amino acid
muc16
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207019764A
Other languages
English (en)
Korean (ko)
Other versions
KR20200096958A (ko
Inventor
지안 얀
안나 슬래거
브래들리 가먼
닐 쿠치
Original Assignee
이노비오 파마수티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노비오 파마수티컬즈, 인크. filed Critical 이노비오 파마수티컬즈, 인크.
Priority to KR1020237025314A priority Critical patent/KR20230116957A/ko
Priority to KR1020237025307A priority patent/KR20230116955A/ko
Priority to KR1020237025306A priority patent/KR20230116954A/ko
Publication of KR20200096958A publication Critical patent/KR20200096958A/ko
Application granted granted Critical
Publication of KR102560562B1 publication Critical patent/KR102560562B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207019764A 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도 Active KR102560562B1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020237025314A KR20230116957A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025307A KR20230116955A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025306A KR20230116954A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598314P 2017-12-13 2017-12-13
US62/598,314 2017-12-13
US201762599513P 2017-12-15 2017-12-15
US62/599,513 2017-12-15
PCT/US2018/065524 WO2019118764A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting muc16 and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
KR1020237025307A Division KR20230116955A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025306A Division KR20230116954A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025314A Division KR20230116957A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20200096958A KR20200096958A (ko) 2020-08-14
KR102560562B1 true KR102560562B1 (ko) 2023-07-31

Family

ID=66734389

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207019764A Active KR102560562B1 (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025307A Abandoned KR20230116955A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025306A Pending KR20230116954A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025314A Pending KR20230116957A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020237025307A Abandoned KR20230116955A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025306A Pending KR20230116954A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도
KR1020237025314A Pending KR20230116957A (ko) 2017-12-13 2018-12-13 Muc16을 표적화하는 암 백신 및 이의 용도

Country Status (11)

Country Link
US (3) US11235044B2 (https=)
EP (1) EP3723812A4 (https=)
JP (2) JP7441169B2 (https=)
KR (4) KR102560562B1 (https=)
CN (1) CN111741772A (https=)
AU (2) AU2018383662C1 (https=)
BR (1) BR112020010542A2 (https=)
CA (2) CA3204873A1 (https=)
MX (3) MX2020006217A (https=)
RU (1) RU2750689C1 (https=)
WO (1) WO2019118764A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200096954A (ko) * 2017-12-13 2020-08-14 이노비오 파마수티컬즈, 인크. Boris를 표적으로 하는 암 백신 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083866A2 (en) 2001-04-17 2002-10-24 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
US20100331536A1 (en) * 2001-04-17 2010-12-30 O'brien Timothy CA125 gene and its use for diagnostic and therapeutic interventions

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
JP3044062B2 (ja) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0465560B1 (en) 1989-03-31 1996-06-05 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
EP0708659A4 (en) 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDES
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
KR100780158B1 (ko) 1996-10-23 2007-11-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 면역 치료법 및 개량 백신
JP2001520537A (ja) 1997-04-03 2001-10-30 エレクトロフェクト・アクティーゼルスカブ 医薬品と核酸の骨格筋への導入方法
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
IL138075A0 (en) 1998-02-27 2001-10-31 Univ Pennsylvania Vaccines, immunotherapeutics and methods for using the same
EP1100579B1 (en) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
US20030078399A1 (en) * 2001-05-11 2003-04-24 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
EP1628749B1 (en) 2003-05-30 2019-07-31 VGXI, Inc. Devices and methods for biomaterial production
US8008265B2 (en) 2003-06-13 2011-08-30 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CA2544946A1 (en) 2003-11-24 2005-03-06 Sidney Kimmel Cancer Center Mucin antigen vaccine
WO2007050095A2 (en) 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
KR101421745B1 (ko) 2006-01-13 2014-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 코돈 최적화된 ｉｌ―15를 사용하는 백신 및 면역치료제, 및 그의 사용 방법
ES2993941T3 (en) 2006-10-17 2025-01-14 Inovio Pharmaceuticals Inc Electroporation devices for electroporation of cells in mammals
EP2153260B1 (en) 2007-05-23 2017-01-25 VGXI, Inc. Composition comprising high concentration of biologically active molecules and processes for preparing the same
WO2009032974A2 (en) * 2007-09-06 2009-03-12 Tripath Imaging, Inc. Nucleic acid-based methods for the detection of ovarian cancer
US10071154B2 (en) 2008-04-04 2018-09-11 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
WO2010037124A1 (en) 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
CN102821790A (zh) 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法
CA2788902C (en) 2010-02-08 2019-09-03 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
US9057107B2 (en) 2011-03-08 2015-06-16 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
CN102321923B (zh) * 2011-05-30 2014-04-16 江苏大学 肿瘤粘蛋白糖肽抗原决定部位的单克隆抗体库的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083866A2 (en) 2001-04-17 2002-10-24 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
US20100331536A1 (en) * 2001-04-17 2010-12-30 O'brien Timothy CA125 gene and its use for diagnostic and therapeutic interventions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200096954A (ko) * 2017-12-13 2020-08-14 이노비오 파마수티컬즈, 인크. Boris를 표적으로 하는 암 백신 및 이의 용도
KR102668476B1 (ko) 2017-12-13 2024-05-23 이노비오 파마수티컬즈, 인크. Boris를 표적으로 하는 암 백신 및 이의 용도
US12161706B2 (en) 2017-12-13 2024-12-10 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting BORIS and uses thereof

Also Published As

Publication number Publication date
KR20230116957A (ko) 2023-08-04
AU2022287652A1 (en) 2023-02-02
EP3723812A4 (en) 2022-02-16
US12285473B2 (en) 2025-04-29
JP2024023358A (ja) 2024-02-21
US20220111026A1 (en) 2022-04-14
EP3723812A1 (en) 2020-10-21
AU2018383662C1 (en) 2023-02-09
JP2021506254A (ja) 2021-02-22
BR112020010542A2 (pt) 2020-12-01
MX2022015822A (es) 2023-01-24
RU2750689C1 (ru) 2021-07-01
US11235044B2 (en) 2022-02-01
KR20230116955A (ko) 2023-08-04
KR20200096958A (ko) 2020-08-14
RU2021118706A (ru) 2021-08-03
KR20230116954A (ko) 2023-08-04
CN111741772A (zh) 2020-10-02
MX2020006217A (es) 2020-12-03
AU2018383662B2 (en) 2022-09-29
CA3084135C (en) 2024-03-05
US20250222086A1 (en) 2025-07-10
US20190175708A1 (en) 2019-06-13
WO2019118764A1 (en) 2019-06-20
AU2018383662A1 (en) 2020-07-16
CA3204873A1 (en) 2019-06-20
MX2022015820A (es) 2023-01-24
CA3084135A1 (en) 2019-06-20
JP7441169B2 (ja) 2024-02-29

Similar Documents

Publication Publication Date Title
US20220265801A1 (en) Cancer Vaccines Targeting PRAME and Uses Thereof
US20250222086A1 (en) Cancer vaccines targeting muc16 and uses thereof
JP7659599B2 (ja) サバイビンを標的とするがんワクチンおよびその使用
JP7554320B2 (ja) メソセリンを標的とするがんワクチンおよびその使用
US12161706B2 (en) Cancer vaccines targeting BORIS and uses thereof
RU2777918C2 (ru) Противораковые вакцины, направленные на muc16, и их применение
HK40034676A (en) Cancer vaccines targeting muc16 and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200708

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200709

Comment text: Request for Examination of Application

PG1501 Laying open of application
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220314

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221027

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220314

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20221027

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220614

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201230

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200709

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20230425

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230329

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20221027

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220614

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201230

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200709

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230724

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230724

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230725

End annual number: 3

Start annual number: 1

PG1601 Publication of registration